US 11,944,613 B2
CYP2J2 antagonists in the treatment of pain
Marco Sisignano, Frankfurt (DE); Christian Brenneis, Kleinostheim (DE); Klaus Scholich, Steinbach (DE); Gerd Geisslinger, Bad Soden (DE); Sebastian Zinn, Frankfurt (DE); and Michael John Parnham, Bad Soden (DE)
Assigned to FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V., Munich (DE)
Filed by FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V., Munich (DE)
Filed on Oct. 7, 2019, as Appl. No. 16/594,790.
Application 16/594,790 is a continuation of application No. 15/503,643, abandoned, previously published as PCT/EP2015/068767, filed on Aug. 14, 2015.
Claims priority of application No. 14181086 (EP), filed on Aug. 14, 2014; and application No. 14186624 (EP), filed on Sep. 26, 2014.
Prior Publication US 2020/0101055 A1, Apr. 2, 2020
Int. Cl. A61K 31/445 (2006.01); A61K 31/138 (2006.01); A61K 31/198 (2006.01); A61K 31/216 (2006.01); A61K 31/4184 (2006.01); A61K 31/437 (2006.01); A61K 31/4545 (2006.01); A61K 31/495 (2006.01); A61K 31/496 (2006.01); A61K 31/498 (2006.01); A61K 31/517 (2006.01); A61K 31/558 (2006.01); A61K 31/565 (2006.01); A61K 31/567 (2006.01); A61K 31/573 (2006.01); A61K 31/58 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/445 (2013.01) [A61K 31/138 (2013.01); A61K 31/198 (2013.01); A61K 31/216 (2013.01); A61K 31/4184 (2013.01); A61K 31/437 (2013.01); A61K 31/4545 (2013.01); A61K 31/495 (2013.01); A61K 31/496 (2013.01); A61K 31/498 (2013.01); A61K 31/517 (2013.01); A61K 31/558 (2013.01); A61K 31/565 (2013.01); A61K 31/567 (2013.01); A61K 31/573 (2013.01); A61K 31/58 (2013.01); A61K 45/06 (2013.01)] 6 Claims
 
1. A method for treating chemotherapy induced peripheral neuropathic pain (CIPNP) in a subject in need of the treatment, the method comprising:
administering to the subject a therapeutically effective amount of a cytochrome P450 epoxygenase 2J2 (CYP2J2) antagonist to treat the CIPNP, the CYP2J2 antagonist selected from the group consisting of estradiol, clobetasol propionate, doxazosin mesylate, fenofibrate, levonorgestrel, aripiprazole, halcinonide, telmisartan, levothyroxine-Na, alosetron-HCl, fluocinonide, and liothyronine-Na.